// App-Quantinova.ai

2125 : Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

Researchers

Presenter

  • Joseph Merola

Principal Investigators

  • Iain B McInnes

  • Arthur Kavanaugh

  • Peter Nash

  • Zhenyi Xue

  • Vassilis Stakias

  • Ann Eldred

  • Sandra Ciecinski

  • Kevin Douglas

  • Laura Coates

Medical Centers

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • University of California, San Diego, La Jolla, CA

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved